Monte Rosa Therapeutics, Inc.

NASDAQ•GLUE

CEO: Dr. Markus Warmuth M.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-06-24

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

連絡先情報

321 Harrison Avenue, Suite 900, Boston, MA, 02118, United States

617-949-2643

www.monterosatx.com

時価総額

$1.04B

PER (TTM)

63.1

17.5

配当利回り

52週高値

$25.77

52週安値

$3.50

52週レンジ

56%

順位61Top 91.5%

2.0

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$12.77M+38.54%

直近4四半期の推移

EPS

-$0.33+13.79%

直近4四半期の推移

フリーCF

$99.78M-566.40%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Collaboration Revenue Soars Nine-month collaboration revenue reached $120.9M, up $105.9M, driven by Roche and Novartis agreements.

Nine-Month Profitability Achieved Swung to $7.5M net income for nine months, reversing prior year's $86.1M net loss.

Major Novartis Deal Closed Received $120.0M upfront payment from September 2025 Novartis deal, supporting future development.

Strong Liquidity Position Cash, cash equivalents, and marketable securities totaled $396.2M, supporting operations for at least twelve months.

リスク要因

Continued Operating Losses Expected Expect continued significant operating losses and negative cash flows as product development continues indefinitely.

High R&D Spending Increases Nine-month R&D expenses rose $16.8M to $99.5M, driven by clinical trial advancements and pipeline progression.

Future Financing Uncertainty Additional funding is necessary for future research; success in raising capital on acceptable terms is not assured.

Clinical Trial Execution Risk Successful development and regulatory approval of product candidates remain highly uncertain, costly, and time-consuming endeavors.

見通し

MRT-8102 Trial Results Due Initial safety and tolerability results from MRT-8102 Phase 1 study anticipated in the first half of 2026.

Novartis Collaboration Advancement Applying proprietary QuEEN™ engine for discovery/development of degraders under the new September 2025 agreement.

Funding Runway Confirmed Existing cash resources expected to fund operating expenses and capital needs for at least the next twelve months.

Deferred Revenue Recognition Remaining deferred revenue from Novartis agreements expected to be recognized over the next 36 to 60 months.

同業比較

売上高 (TTM)

ARVN

$262.60M

-0.3%

KROS

$244.06M

+6775.0%

VALN

$198.55M

+13.5%

粗利益率 (最新四半期)

VIR

672.1%

-54902.1pp

DNA

124.4%

-21.7pp

ATXS

100.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ERAS	$4.54B	-33.4	-34.5%	11.9%
DAWN	$2.20B	-20.5	-23.4%	0.5%
NRIX	$1.35B	-5.6	-57.5%	8.1%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-40.5%

成長鈍化

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

50%

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月19日

EPS:-$0.45

売上高:$17.09M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし